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ABSTRACT
Introduction: The objective of this subgroup
analysis is to investigate the effectiveness of
liraglutide in people with type 2 diabetes (T2D)
treated within the primary care physician (PCP)
and specialist care settings.
Methods: EVIDENCE is a prospective,
observational study of 3152 adults with T2D
recently starting or about to start liraglutide
treatment in France. We followed patients in
the PCP and specialist settings for 2 years to
evaluate the effectiveness of liraglutide in
glycemic control and body weight reduction.
Furthermore, we evaluated the changes in
combined antihyperglycemic treatments, the
reasons for prescribing liraglutide, patient
satisfaction, and safety of liraglutide in these
two treatment settings.
Results: After 2 years of follow-up, 477 out of
1209 (39.0%) of PCP and 297 out of 1398
(21.2%) of specialist-treated patients still used
liraglutide and maintained the glycated
hemoglobin (HbA1c) target of \7.0%.
Significant reductions from baseline were
observed in both PCP- and specialist-treated
cohorts in mean HbA1c (-1.22% and -0.8%,
respectively), fasting plasma glucose (FPG)
concentration (-39 and -23 mg/dL), body
weight (-4.4 and -3.8 kg), and body mass
index (BMI) (-1.5 and -1.4 kg/m2), all
p\0.0001. Reductions in HbA1c and FPG were
significantly greater among PCP- compared
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with specialist-treated patients, p\0.0001 for
both. Patient treatment satisfaction was also
significantly increased in both cohorts.
Reported gastrointestinal adverse events were
less frequent among PCP-treated patients
compared with specialist-treated patients
(4.5% vs. 16.1%).
Conclusion: Despite differences in demography
and clinical characteristics of patients treated for
T2D in PCP and specialty care, greater reduction in
HbA1c and increased glycemic control durability
were observed with liraglutide in primary care,
compared with specialist care. These data suggest
that liraglutide treatment could benefit patients in
primary care by delaying the need for further
treatment intensification.
Trial Registration: ClinicalTrials.gov identifier,
NCT01226966.
Funding: Novo Nordisk A/S.
Keywords: GLP-1 receptor agonist; Liraglutide;
Observational study; Primary care; Type 2
diabetes; Weight management
INTRODUCTION
Management of hyperglycemia in type 2
diabetes (T2D) depends upon on a variety of
patient- and disease-specific factors [1]. In the
case of metformin not being sufficient to
achieve appropriate glycemic control, patients
require intensification by adding a new
therapeutic agent. One option recommended
by the American Diabetes Association/European
Association for the Study of Diabetes (ADA/
EASD) position statement and American
Association of Clinical Endocrinologists and
American College of Endocrinology (AACE/
ACE) guidelines is the introduction of a
glucagon-like peptide-1 receptor agonist
(GLP-1RA) as a second-line therapy [1, 2]. In
the case of the AACE/ACE guidelines, GLP-1RAs
are the first-choice second-line therapy.
Liraglutide is a once-daily GLP-1RA for the
treatment of T2D that has been shown to offer
effective glycemic control, benefits in body
weight reduction, improved measures of b-cell
function, and a low risk of hypoglycemia. This
was demonstrated in the Liraglutide Effect and
Action in Diabetes (LEAD) phase 3 randomized
clinical trials (RCT) program, in which
liraglutide was used both as monotherapy and
combined with other glucose-lowering agents
[3–9]. Recently, a cardiovascular outcomes trial
to determine the long-term effects of liraglutide
on cardiovascular safety in patients with T2D at
high cardiovascular risk (LEADER) showed that
liraglutide significantly reduced the risk of
major adverse cardiovascular events [10].
Compared with RCTs, observational studies
are conducted with less strict inclusion and
exclusion criteria. Furthermore, they are less
costly and can be used to study larger numbers
of people in a wider range of environments. This
provides crucial real-world evidence (RWE) from
routine clinical practice that may be generalized
to a broader population, despite that they provide
less monitoring of patients, which may result in
under-reporting of adverse events (AEs) [11, 12].
Results from the EVIDENCE study have already
been published, showing the effectiveness of
liraglutide in real-world clinical practice to be
similar to that observed in RCTs, but with a lower
incidence of gastrointestinal AEs [13]. However,
these data previously amalgamated outcomes in
patients prescribed liraglutide by (and followed
by) both primary care physicians (PCPs) and
specialists (diabetologists and endocrinologists).
Given that the majority of patients with T2D are
treated in a PCP setting, PCPs play a crucial role at
the front-line of T2D management in the earlier
stages of the disease. Patients treated by PCPs are
likely tobe characterizeddifferently frompatients
managed in a specialist setting in regards to
demographic and clinical distinctions; therefore,
it is of clinical interest to assess the real-world
effectiveness of liraglutide in these patients
separately. The aim of the present subgroup
analysis is to examine the effectiveness of
liraglutide in the two specific patient subgroups
that constitute the original study cohort: those
treated by PCPs and those treated by specialists.
METHODS
The study methodology has been outlined
previously [13] and is summarized below. All
procedures followed were in accordance with
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ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Declaration of Helsinki,
1964, as revised in 2013. Informed consent was
obtained from all patients for participation in
the study.
Study Design
The observational, prospective, multicenter
EVIDENCE study was conducted in France
between September 2010 and November 2013,
in adults with T2D who had recently started or
were about to start treatment with liraglutide
[13]. PCPs and specialists already treating
patients with diabetes and prescribing
injectable antihyperglycemic treatments were
randomly recruited and asked to include the
first two or three consecutive patients meeting
the eligibility criteria. The inclusion and
exclusion criteria were published previously
[13]. Data related to glycemic control, AEs
(including medical events of special interest
[MESI]), demographic characteristics, vital
signs, and treatment satisfaction were
collected by physicians during routine care at
inclusion (visit 1), then at approximately
3 months (visit 2), 6 months (visit 3),
12 months (visit 4), 18 months (visit 5), and
24 months (visit 6).
Outcome Measures
Endpoints in this subgroup analysis are the
same as those evaluated in the original
EVIDENCE study, but specified for the PCP
and specialist patient subgroups [13]. The
primary endpoint of the original study was the
percentage of patients still using liraglutide and
meeting the ADA target of glycated hemoglobin
(HbA1c)\7.0% [1] at 2 years of follow-up.
Secondary endpoints included change in
antihyperglycemic treatment, change in
HbA1c, change in fasting plasma glucose (FPG),
change in body weight and body mass index
(BMI), patient satisfaction with diabetes
treatment as measured using the Diabetes
Treatment Satisfaction Questionnaire (DTSQ)
and DTSQ change, evaluation of the reasons for
prescription of liraglutide, and safety of
liraglutide (hypoglycemic episodes, AEs, and
MESI). Hypoglycemic episodes within the
4 weeks preceding each visit were reported by
the patients and classified as minor (not
requiring third-party intervention) or
major/severe (requiring third-party
intervention). MESI included pancreatitis,
thyroid gland anomalies, malignant
neoplasias, and major hypoglycemic events.
Definition of Study Populations
The EVIDENCE cohort was divided into
multiple analysis sets. Definitions of the
different analysis sets visit have been outlined
previously [13], but briefly: the full analysis set
(FAS) included all patients attending the
inclusion visit and for whom liraglutide was
prescribed; the effectiveness analysis set (EAS)
included all patients already included in the FAS
who completed the 2-year final visit under
treatment with liraglutide, and with at least
one measurement of HbA1c, FPG, body weight,
or hypoglycemia information at the end of the
study; the population for primary endpoint
analysis (PEA) included all EAS patients plus
patients discontinuing liraglutide treatment but
who remained in the study; and the
patient-reported outcomes analysis set
(PROAS) included all patients in the FAS who
also filled in at least one item on the patient
questionnaire at the inclusion visit and at least
one follow-up. Changes in HbA1c, FPG
concentration, body weight, and BMI from
baseline to 2 years were analyzed using the
EAS population, whereas baseline
characteristics, change in treatment,
motivating factors (for prescription of
liraglutide), and AEs were all analyzed using
the FAS population.
Statistical Analysis
The statistical methodology was described
previously for the overall patient cohort [13].
The present subanalysis examines changes from
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baseline to end-of-study in the two separate
patient cohort subgroups, treated in the PCP
and specialist settings, in the same way as the
original overall analysis [13]. In addition,
between-group statistical comparisons of both
baseline characteristics and secondary efficacy
endpoints using the Wilcoxon rank-sum test




Baseline characteristics of patients from the PCP
(N = 1398) and specialist (N = 1754) cohorts are
presented in Table 1. PCP-treated patients were
on average significantly older (60.1 vs.
57.6 years, p\0.0001), significantly more
likely to be male (55.7% vs. 50.9%, p\0.01),
and had a significantly shorter duration of
diabetes (8 vs. 10 years, p\0.0001),
significantly lower body weight (92.6 vs.
98.1 kg, p\0.0001), significantly lower BMI
(32.8 vs. 35.1 kg/m2, p\0.0001), and similar
HbA1c (8.53% vs. 8.56%, p = 0.83) and FPG
levels (182 vs. 182 mg/dL, p = 0.58) compared
with specialist-treated patients. The proportion
of patients with at least one complication at
baseline was lower in the specialist-treated
cohort compared with the PCP-treated cohort
(28.3% vs. 37.6%).
Primary Endpoint
In total, 472 out of 1209 patients (39.0%) of the
PCP-treated PEA population were still treated
with liraglutide and achieved the target of
HbA1c\7.0% at 2 years of follow-up. In
comparison, 297 out of 1398 patients (21.2%)
in the specialist cohort were still treated with
liraglutide and achieved the target of HbA1c
\7.0% at the end of the study (Fig. 1). In total
(based on a percentage of the complete analysis
population, FAS), 1054 PCP-treated patients
(75.4%) and 975 specialist-treated patients
(55.6%) completed 2 years of liraglutide
treatment.
Secondary Endpoints
Change in Antihyperglycemic Treatment
from Baseline
An average 29.1% of PCP-treated patients were
on monotherapy before liraglutide initiation,
compared with only 11.0% among the
specialist-treated patients; 43.2% of
PCP-treated patients had been on a
combination of two drugs when liraglutide
was initiated. In the specialist-treated cohort,
the majority of patients were treated with three
or more agents when initiating liraglutide
(Table 2). Approximately half the number of
PCP-treated patients were taking insulin before
initiation of liraglutide compared with
specialist-treated patients (8.1% vs. 18.2%).
After 2 years, these proportions remained fairly
similar, with a greater proportion of
specialist-treated patients than PCP-treated
patients taking more than three therapies
(13.4% vs. 28.5%). After 2 years, the
proportion of specialist-treated patients using
insulin had increased to 35.8%, a markedly
greater increase than that seen among
PCP-treated patients (to only 13.6% of patients).
The need to improve glycemic (80.8% vs.
81.4%) and body weight control (58.7% vs.
74.0%) was the most common strongest
motivation given for prescription of liraglutide
in PCP and specialist cohorts, respectively
(Supplementary Table S1).
Glycemic and Body Weight Control
Changes in HbA1c, FPG concentration, body
weight, and BMI from baseline to 2 years were
analyzed on the basis of data from the EAS
population. From baseline to end of study, a
significant mean reduction in HbA1c was
observed in PCP- and specialist-treated
patients (-1.22% and -0.80%, respectively,
p\0.0001 for both, Table 3). Mean FPG
reduction from baseline was significant:
-39 mg/dL in PCP-treated patients and
-23 mg/dL among specialist-treated patients
(p\0.0001 for both). Changes in HbA1c and
FPG from baseline were significantly greater for
PCP-treated patients compared with those
treated by specialists, p\0.0001 for both.
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Table 1 Baseline characteristics







Mean ± SD, years 60.1 ± 10.5 57.6 ± 10.4 \0.0001
Gender
Male, n (%) 778 (55.7) 893 (50.9) \0.01
Female, n (%) 620 (44.3) 861 (49.1)
Duration of diabetes
Median (IQR), years 8 (5–12) 10 (5–15) \0.0001
At least one complication, n (%) 393 (28.3) 655 (37.6) \0.0001
If yes, type of complicationa
Coronary disease, n (%) 163 (11.7) 201 (11.5) 0.86
Neuropathy, n (%) 87 (6.3) 190 (10.9) \0.0001
Retinopathy, n (%) 95 (6.8) 157 (9.0) 0.03
Nephropathy, n (%) 57 (4.1) 183 (10.5) \0.0001
Lower limb arteritis, n (%) 83 (6.0) 93 (5.3) 0.44
Cerebrovascular disease, n (%) 28 (2.0) 41 (2.4) 0.52
Diabetic foot, n (%) 42 (3.0) 28 (1.6) \0.01
Other, n (%) 28 (2.0) 82 (4.7) \0.0001
Clinical characteristics
Body weight
Mean ± SD, kg 92.6 ± 19.3 98.1 ± 20.2 \0.0001
BMI
Mean ± SD, kg/m2 32.8 ± 6.9 35.1 ± 6.7 \0.0001
Systolic blood pressure
Mean ± SD, mmHg 134.6 ± 11.4 134.7 ± 14.6 0.16
Diastolic blood pressure
Mean ± SD, mmHg 77.4 ± 8.0 78.1 ± 9.4 0.14
Laboratory characteristics
HbA1c
Mean ± SD, % 8.53 ± 1.48 8.56 ± 1.5 0.83
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Body weight (-4.4 and -3.8 kg) and mean BMI
(-1.5 and -1.4 kg/m2) were also significantly
reduced from baseline in both PCP- and
specialist-treated patients (all p\0.0001,
Table 3). Reductions from baseline, although
numerically greater within the PCP cohort, were
not significantly greater than that seen among
specialist-treated patients (p = 0.09 for weight
and p = 0.15 for BMI).
Treatment Satisfaction
Throughout the study, patient treatment
satisfaction with liraglutide in PCP-treated
patients increased with an initial DTSQ status
score by 7.52, from amean (±SD) of 20.75± 6.93
(range1.0–36.0) at baseline to28.27± 5.57 (range
7.0–36.0) at the end of the study (p\0.0001). In
specialist-treatedpatients, therewasan increaseof
5.47, from 23.47± 8.02 (range 0.0–36.0) at
baseline to 28.95 ± 6.07 (3.0–36.0) at the end of
the study after 24 months (p\0.0001).
Change in satisfaction with treatment
(compared with previous treatment) after
1 year follow-up, measured by the DTSQ
change, was improved on average 10.54 ± 5.69
(range 10.13–10.96) among PCP-treated
patients and 10.89 ± 6.49 (range 10.40–11.37)
among those treated by specialists.
Hypoglycemia
The percentage of PCP-treated patients with at
least one episode of hypoglycemia (within
4 weeks prior to each visit) decreased during
the study, from 2.8% at 3 months to 1.0% at the
end of the study. Among specialist-treated
patients, incidence of hypoglycemia also
decreased, from 11.4% to 7.9%. Major
hypoglycemia was very rare with a slight
increase in incidence from 0.1% to 0.3%, and
decrease from 0.2% to 0.0% in PCP and
specialist-treated patients, respectively.
Adverse Events and MESI
In total, at least one AE was reported in 158
(11.3%) and 495 (28.2%) PCP-treated and
specialist-treated patients, respectively, during
the study period. AE categories affecting at least
1.0% of the population are listed in Table 4.
In addition, there was one serious AE of
nausea observed in each subgroup. The most
commonly reported AEs in both subgroups were
Table 1 continued







Mean ± SD, mg/dL 182 ± 61 182 ± 62 0.58
As a result of missing data, the % value relates to the number of patients analyzed within the FAS population for that
particular characteristic and not the total FAS population. P values for intergroup comparisons were conducted using the
Wilcoxon rank-sum test unless variable is dichotomous, in which case the Chi2 test was used
BMI body mass index, FAS full analysis set, FPG fasting plasma glucose, HbA1c glycated hemoglobin, IQR interquartile
range, n number of patients, SD standard deviation
a Patients may have had more than one complication
Fig. 1 Patients still treated with liraglutide achieving
primary endpoint of HbA1c\7.0% at 2 years of treatment.
95% conﬁdence intervals shown. Analysis based on
population for primary endpoint analysis (PEA). HbA1c
glycated hemoglobin, PCP primary care physician
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gastrointestinal in nature, with a frequency of
4.5% in the PCP cohort and 16.1% in the
specialist cohort. Four cases of acute
pancreatitis were observed in the specialist
cohort in addition to one case of chronic
pancreatitis reported in both cohorts. One
pancreatic neoplasm was observed in one
patient within the specialist-treated cohort.
DISCUSSION
Liraglutide treatment was associated with
sustained glycemic control both in PCP and
specialist settings, with 39.0% of PCP-treated
patients and 21.2% of specialist-treated patients
still under treatment and achieving HbA1c
\7.0% after 2 years of follow-up. This
highlights that PCP-treated as well as
specialist-treated patients can both meet
glycemic targets and maintain control over
extended periods of time, rather than for the
usually shorter period of an RCT.
Importantly, for all clinical outcomes,
patients included in this PCP cohort showed
more favorable clinical responses than the
specialist cohort, most notably in HbA1c and
FPG responses, for which the reductions were
significantly greater among PCP-treated
patients. This suggests that the
specialist-treated cohort may have included
those selected patients who had previously
been more challenging to treat in primary
practice. The more challenging nature of the
specialist-treated cohort is evidenced by the fact
that there were several baseline differences
between the cohorts in this study: PCP-treated
patients, on average, had a significantly shorter
duration of diabetes, significantly lower BMI,
and fewer complications compared with
Table 2 Change in antihyperglycemic treatment from before initiation of liraglutide to the end of study
Before initiation
of liraglutide (EAS)
At end of inclusion
visit (0 months) (EAS)
At end of study
(2 years) (FAS/EAS)
PCP Specialist PCP Specialist PCP Specialist
Therapeutic strategy
Monotherapy 303 (29.1%) 106 (11.0%) 62 (6.0%) 13 (1.4%) 57 (6.0%) 11 (1.3%)
Double therapy 450 (43.2%) 371 (38.3%) 501 (48.6%) 294 (30.6%) 419 (44.1%) 202 (24.2%)
Triple therapy 249 (23.9%) 418 (43.2%) 370 (35.9%) 518 (53.9%) 348 (36.6%) 385 (46.1%)
[3 therapies 39 (3.7%) 73 (7.5%) 98 (9.5%) 136 (14.2%) 127 (13.4%) 238 (28.5%)
Treatment
Biguanides 817 (78.5%) 851 (87.9%) 786 (76.2%) 862 (89.7%) 779 (76.7%) 844 (88.7%)
SUs 531 (51.0%) 600 (62.0%) 428 (41.5%) 564 (58.4%) 438 (43.1%) 564 (59.4%)
DPP-4 inhibitors 361 (34.7%) 444 (45.9%) 124 (12.0%) 58 (6.0%) 133 (13.1%) 58 (6.1%)
Insulin 84 (8.1%) 176 (18.2%) 61 (5.9%) 104 (10.8%) 133 (13.6%) 307 (35.8%)
Glitazones 155 (14.9%) 129 (13.3%) 60 (5.8%) 61 (6.3%) 39 (3.8%) 21 (2.2%)
Glinides 66 (6.3%) 92 (9.5%) 48 (4.6%) 76 (7.9%) 65 (6.4%) 107 (11.2%)
a-Glucosidase inhibitors 49 (4.7%) 51 (5.3%) 35 (3.4%) 26 (2.7%) 34 (3.3%) 42 (4.4%)
Values are expressed as n (%); as a result of missing data, the % value relates to the number of patients analyzed within the
EAS population for that particular time point and not the total FAS or EAS population
DPP-4 dipeptidyl peptidase-4, EAS effectiveness analysis set, FAS full analysis set, n number of patients in the subset, PCP
primary care physician, SUs sulfonylureas
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specialist-treated patients. Furthermore, more
patients used liraglutide in addition to three or
more than three therapies, or in combination
with insulin, if they were treated by specialists,
indicating that these patients had a more
complex disease history than those treated in
the PCP setting. This is also reflected by
previous oral antidiabetic drug monotherapy
being more common among PCP-treated
patients than specialist-treated patients before
initiation of liraglutide. Over the 2 years of
follow-up, concomitant antihyperglycemic
therapy evolved steadily in both subgroups,
underlining the progressive course of disease in
both groups. Notably, the proportion of
specialist-treated patients taking insulin after
2 years had increased markedly.
There is already a wealth of RWE on the
effectiveness of liraglutide showing it to be
effective in reducing and maintaining
reductions in HbA1c and body weight in
different contexts, including Indian [14],
Japanese [15], and European [16] populations,
in some cases up to 3 years post-treatment
initiation [17]. These findings were verified in
a recent systematic review of observational data
[18]. Real-life clinical data assessed in an audit
by The Association of British Clinical
Diabetologists (ABCD) demonstrated that, after
6 months of treatment, liraglutide had
effectively reduced HbA1c and was well
tolerated [19, 20]. Additionally, data from the
IMS Health integrated claims database in the
USA demonstrated that, in clinical practice,
liraglutide provides greater HbA1c reductions
and achievement of glycemic target compared
with exenatide and the dipeptidyl peptidase-4
(DPP-4) inhibitor sitagliptin, in patients with
T2D [21].
The results of this subgroup analysis of the
EVIDENCE study suggest that liraglutide, when
prescribed by and followed by a PCP in real-life
practice, has an effectiveness and safety profile
consistent with that observed in RCTs [3–9] as
well as RWE studies [19–21], indicating that
liraglutide is effective in achieving target and
maintaining glycemic control in the long term
in a PCP management setting. The achievement
of significantly greater reductions in HbA1c and
FPG in the PCP setting is likely to be related to
patient baseline characteristics, but may also
indicate that empowerment of PCPs to initiate
liraglutide treatment at an earlier stage could
reduce the chance of developing complications,
by achieving greater and prolonged HbA1c
reductions.
In the current study, patients in both cohorts
were, on average, slightly older andwith a higher
prevalence of obesity than those included in the
LEADstudies,wheremeanagewas55.7 years and











-1.22 [-1.31; -1.12], p\0.0001* -0.80 [-0.90; -0.71], p\0.0001* \0.0001
Change in FPG,
mg/dL [95% CI]
-39 [-44; -34], p\0.0001* -23 [-29; -17], p\0.0001* \0.0001
Change in body weight,
kg [95% CI]
-4.4 [-4.8; -3.9], p\0.0001* -3.8 [-4.2; -3.4], p\0.0001* 0.09
Change in BMI,
kg/m2 [95% CI]
-1.5 [-1.70; -1.38], p\0.0001* -1.4 [-1.52; -1.23], p\0.0001* 0.15
Mean change from baseline to end of study
BMI body mass index, CI conﬁdence interval, FPG fasting plasma glucose, HbA1c glycated hemoglobin, PCP primary care
physician
* p values refer to the Wilcoxon rank-sum test as a within-group comparison of change from baseline
 p values refer to the Wilcoxon rank-sum test as a between-group comparison of change from baseline
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mean BMI 31.9 kg/m2 [22]. Additionally, a
number of both PCP- and specialist-treated
patients had previously been treated with
insulin prior to liraglutide initiation in the
EVIDENCE study, which was considered as an
exclusion criterion for the LEAD studies [3–9].
The median duration of diabetes in patients
included in the EVIDENCE study was 8 years
(PCP cohort) and 10 years (specialist cohort),
compared with 5.4–9.4 years in the LEAD studies
[3–9]. This suggests that liraglutide was initiated
at a later stage of the disease in the EVIDENCE
study compared with the LEAD studies [13].
However, the baseline HbA1c levels were similar
in the EVIDENCE (8.5%) and LEAD (ca. 8.4%)
studies [22], highlighting the issue of clinical
inertia [23], with delayed treatment
intensification despite suboptimal glycemic
control, for patients with T2D in the real-world
setting. Themean reduction inHbA1cobservedat
the end of the EVIDENCE study for PCP- and
specialist-treated patients was clinically relevant
and comparable to that observed in the LEAD
program [3–9] and in more recent studies with
liraglutide [24, 25], suggesting that clinically
relevant reductions in HbA1c can be achieved in
the real world and that the findings may be
generalized to wider populations.
Table 4 Adverse events—FAS
Adverse event PCP cohort n (%) Specialist cohort n (%)
Total number of patients in analysis set 1398 1754
Gastrointestinal 63 (4.5) 282 (16.1)
Nausea 28 (2.0) 116 (6.6)
Diarrhea 8 (0.6) 55 (3.1)
Vomiting 6 (0.4) 48 (2.7)
Dyspepsia 10 (0.7) 41 (2.3)
Acute pancreatitis 0 (0.0) 4 (0.2)
Chronic pancreatitis 1 (0.1) 1 (0.1)
Hyperlipasemia 0 (0.0) 1 (0.1)
General 22 (1.6) 51 (2.9)
Asthenia 7 (0.5) 14 (0.8)
Cardiovascular disorders 13 (0.9) 28 (1.6)
Atrial ﬁbrillation 3 (0.2) 7 (0.4)
Arrhythmia 2 (0.1) 4 (0.2)
Myocardial infarction 2 (0.1) 4 (0.2)
Coronary stenosis 2 (0.1) 3 (0.2)
Hemorrhagic stroke 0 (0.0) 1 (0.1)
Ischemic stroke 0 (0.0) 1 (0.1)
Transient ischemic attack 1 (0.1) 0 (0.0)
AE categories affecting at least 1.0% of the population are listed. The safety population for AEs included all patients who
were prescribed liraglutide at least once and had at least one available safety data point after inclusion. The n value relates to
the number of AEs for each subset; the % value relates to the proportion of the FAS population affected
AE adverse event, FAS full analysis set, PCP primary care physician
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Although improvement in glycemic control
was the main reason for prescription of
liraglutide, there was a higher proportion of
PCPs as well as specialist care who cited
‘‘improvement in body weight control’’ as a
desired effect. In total, 63.4% and 76.7% of PCP-
and specialist-treated patients, respectively, had
an initial BMI C30 kg/m2, and reductions in
body weight and BMI after 2 years’ follow-up
were statistically significant for both cohorts
and consistent with those reported in RCTs
[3–9] and other studies assessing the
effectiveness of liraglutide [24, 25].
The safety profile of liraglutide in both
cohorts was consistent with previous results.
However, of note is the discrepancy in the rate
of gastrointestinal AEs between the two cohorts,
with a greater proportion of specialist-treated
patients reporting AEs. In addition,
hypoglycemia rates differed between cohorts;
this might reflect the greater use of insulin in
specialist-treated patients, and the perhaps
unexpected decline in hypoglycemia in this
cohort might reflect the insulin dose-sparing
effect of liraglutide. Unfortunately, a limitation
of this analysis is the lack of information on
average dose of insulin, which might have
added information to further understand this
issue. Alternatively, the difference in rate of
hypoglycemia could be attributed to differences
in the way PCPs and specialists reported
hypoglycemia—the design of the study did not
include any hypoglycemia verification test,
allowing for this possibility. Furthermore, on
the basis of the limitations of an observational
study, this study may also be subject to
confounding and selection bias.
CONCLUSION
The results of this subgroup analysis highlight
the effectiveness of liraglutide in terms of
sustained glycemic control and body weight
reduction in patients with T2D treated both in
the PCP and specialist settings, consistent with
results from RCTs and other RWE studies. In
addition, patients treated in the PCP setting
obtained significantly more favorable glycemic
outcomes in terms of HbA1c reduction and
glycemic control durability than those treated
by specialists. Patients treated in a PCP setting
also showed less of a tendency to progress to
more complex treatment regimens. Overall,
these results suggest that liraglutide treatment
could benefit patients in the primary care
setting by delaying the need for further
treatment intensification.
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